Abstract
Background and Objectives Oral delayed-release dimethyl fumarate (DMF) is not recommended during pregnancy and should only be used if the potential benefit justifies the potential fetal risk. Although DMF was well tolerated in clinical trials with consistent safety results in postmarketing surveillance, data are limited in pregnant women. The objective was to provide pregnancy outcomes and DMF exposure information from an interim analysis from a prospective, international registry (TecGistry; NCT01911767).
Methods Women exposed to DMF from the first day of their last menstrual period before conception or during pregnancy were evaluated. Data were obtained at enrollment; 6−7 months' gestation; 4 weeks after estimated due date; and 4, 12, and 52 weeks after birth. Outcomes included live births, gestational size, pregnancy loss, birth defects, and infant or maternal death after delivery. Outcomes were analyzed cumulatively from October 30, 2013 (the start of TecGistry), to April 8, 2020.
Results Of 345 enrolled patients, median (range) age was 32 (20–43) years. The mean (SD) duration of gestational weeks of DMF exposure was 4.9 (3.8). Most infants were full-term at birth (n = 249/274; 91%) and of average gestational size (n = 190/232; 82%). Of 351 outcomes, 277 were live births; 17 (5%) spontaneous abortions (95% confidence interval [CI] 2.6%–7.1%), including 1 (<1%) molar and 1 (<1%) ectopic pregnancy, were reported. There were 8 (2.9% [95% CI 1.3%–5.6%]) adjudicator-confirmed birth defects among the 277 live births.
Discussion Interim results from this large registry indicate that early DMF exposure was not significantly associated with adverse pregnancy outcomes. Outcomes are consistent with previous smaller reports and with the general population.
Trial Registration Information TecGistry; clinical trial registration number: NCT01911767.
Glossary
- DMF=
- dimethyl fumarate;
- CI=
- confidence interval;
- MS=
- multiple sclerosis
The global prevalence of multiple sclerosis (MS) is 2 and up to 4 times higher in women than in men1; a large proportion of women with MS are of childbearing age.1,2 Delayed-release dimethyl fumarate (DMF) is recommended for the treatment of relapsing-remitting MS, but DMF is not recommended during pregnancy. DMF should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus.3 As of June 30, 2021, >535,000 patients have been treated with DMF, representing >1,100,000 patient-years of exposure. No risk of fetal abnormalities or adverse pregnancy outcomes has been observed in relation to DMF exposure in clinical trials, which have shown 97 of 142 (68%) live births, 16 of 142 (11%) spontaneous abortions, 24 of 142 (17%) elective terminations, and 5 of 142 (4%) preterm births (Biogen, Periodic Safety Update Report, May 24, 2018). Nonetheless, additional data are needed from the postmarketing setting.4
There is no known adverse association or mechanism of action related to DMF with pregnancy outcomes. However, a large proportion of women diagnosed with MS are of childbearing age. Therefore, a global registry was established to evaluate whether DMF exposure may affect pregnancy and infant outcomes. Study coordinating centers in 8 countries are enrolling DMF-exposed pregnant women into an ongoing, prospective, observational, international registry (TecGistry; NCT01911767) to assess pregnancy and infant outcomes. We report results from an interim analysis of the registry as of April 8, 2020.
Methods
Participants included pregnant women with MS exposed to DMF since the first day of their last menstrual period before conception or during pregnancy. Women were excluded if diagnosed with abnormalities in prenatal testing or the pregnancy outcome was known at enrollment. Specifically, the evidence of abnormalities found in an ultrasound, amniocentesis, or maternal serum alpha-fetoprotein/serum would exclude the patients. In addition, the following specific infectious diseases would exclude patients: rubella (by titer), toxoplasmosis (by screening), venereal disease research laboratory (rapid plasma screen), hepatitis B (by screening), or triple screen. Otherwise, patients were included and any other potential confounders or causes of abnormalities would be handled analytically. The number of pregnancy outcomes needed to detect a prevalence risk ratio of 2.9 with 80% power was 300. Evaluations consisted of live births (premature birth [<37 weeks] and full-term birth); pregnancy loss (elective or therapeutic pregnancy terminations, spontaneous abortions, and fetal death, including still birth); ectopic and molar pregnancies, birth defects, or congenital anomalies (including minor anomalies) occurring at age ≤52 weeks; any infant death occurring at age ≤52 weeks; and any maternal death occurring ≤12 weeks after delivery. Data were collected at enrollment; 6–7 months of gestation; 4 weeks after estimated delivery date; and 4, 12, and 52 weeks after birth. No information on breastfeeding with DMF or associated outcomes were collected. Outcomes were analyzed cumulatively from October 30, 2013 (the start of TecGistry), to April 8, 2020. The methods used to increase enrollment included increasing the number of coordinating centers, ensuring internal follow-up on pharmacovigilance reports as permitted by local legislation, and improving digital and social outreach to generate greater awareness of the registry in accordance with local guidance and laws.
Potential birth defects were adjudicated by an external teratology expert and classified according to both the Metropolitan Atlanta Congenital Defects Program and/or the European network for the surveillance of congenital anomalies schemas. Gestational size was classified based on the World Health Organization or country-specific growth charts as small (birth weights <2,500 g), appropriate (birth weights 2,500–4,000 g), or large (birth weights >4,000 g). Percentages associated with gestational age and size were based on births with available data. This interim analysis was descriptive in nature. The prevalence of birth defects and 95% confidence intervals (CIs) for the registry population were calculated for this interim analysis. The Clopper-Pearson exact CIs were implemented.
Standard Protocol Approvals, Registrations, and Patient Consents
Participating physicians obtained centralized and/or local ethics committee approval of the protocol, informed consent form, and other required study documents before starting the study. The study was conducted in accordance with the International Conference on Harmonisation and Good Pharmacovigilance Practices guidelines. In accordance with the Declaration of Helsinki, strict respect was given to the patients' privacy; physical, mental, and social integrity; and confidentiality of personal information.
Patient consent (written or verbal per local regulations) was obtained by the reporting healthcare provider, investigator, or coordinating center (if permitted by local regulations) before the patient's enrollment in the registry. If the patient was a minor, written consent was obtained from the parent or legal guardian. A release of medical information was obtained from the patient to permit the coordinating center or reporting healthcare provider to contact healthcare providers related to the pregnancy (e.g., the patient's obstetric health care provider). A release of medical information was also obtained by the enrolling healthcare provider from the parent or the infant's personal representative so that the coordinating center or reporting healthcare provider could contact the pediatric healthcare provider.
Data Availability
This trial is registered on ClinicalTrials.gov (NCT01911767). The data sets generated during this study are available on request through the Biogen Data Request Portal (biogenclinicaldatarequest.com).
Results
Of 345 enrolled patients in this pregnancy registry, there were 351 known or anticipated outcomes (Figure): 243 from Germany, 65 from the United States, 16 from the United Kingdom, 9 from Italy, 8 from Australia, and 2 each from Canada and Ireland. Mean (SD) gestational week of enrollment was 11.9 (8.1). Earliest DMF exposure occurred in the first (>99%; 341/342) and second (<1%; 1/342) trimesters in the 342 women with a known exposure date (Table 1). Of 351 observed or expected pregnancy outcomes, 17 (5%) spontaneous abortions, including 1 ectopic and 1 molar pregnancy, were reported (Table 2). One neonatal death was reported, and no maternal or perinatal deaths were reported.
a Some pregnancies resulted in multiple (twin) births. b Known or anticipated outcomes; missing patients may have known pregnancy outcomes but further follow-up is in progress or not yet complete. c Percentages based on births with available birth status n = 296 because 1 patient had missing data.
Patient Characteristics at the Time of Enrollment and DMF Exposure
Incidences of Pregnancy and Infant Outcomes
The median (range) duration of gestational DMF exposure was 5 weeks (0–40), and more than 99% of pregnancies were only exposed to disease-modifying therapy in the first trimester (Table 1). There were 277 live births; of these, 7 were from 4 sets of twin pregnancies. Of live births with known results, most infants were full-term at birth (n = 249/274; 91%) and 25 (9%) were premature. Of the 232 infants with neonatal weight data, 26 (11%) were classified as small, 190 (82%) as appropriate, and 16 (7%) as large. Of 277 live births, there were 8 (2.9% [95% Clopper-Pearson exact CI 1.3%–5.6%]) confirmed birth defects (Table 2). Eighty-six percent (232/271) of women indicated they breastfed their infants at any time after birth.
Discussion
Interim results from this large, international registry indicate that DMF exposure in the first trimester was not significantly associated with adverse pregnancy outcomes. The proportion of spontaneous abortions is less than that reported in MS clinical trials (8%)4 and in the general US population (12%–16%).5 Compared with the 3% of birth defects reported in the registry, birth defects are detected in 4% of people with MS6 and in 2%–5% of the general population.7 The prevalence of ventricular septal defect is estimated to range from 192 to 1,045 per 100,000 live births,8,-,10 whereas the prevalence in this registry was 722 per 100,000 live births.
Most women indicated they breastfed their infants. Very low excretion of DMF in breast milk has been demonstrated by 2 recent case reports.11 This is currently under investigation.
There are several limitations to this analysis. At the time of this data cut and analysis, 300 pregnancy outcomes (the targeted number of patients needed to detect a prevalence risk ratio of 2.9 with 80% power, assuming an expected prevalence of birth defects of 2.2%) had not been observed, limiting the potential to draw final conclusions. Subsequent enrollment and follow-up of pregnancies will enable more detailed and robust analyses. Most exposure occurred in the first trimester with only a single pregnant woman and fetus exposed in the second trimester, suggesting minimal exposure to DMF during pregnancy and in utero in this registry. Thus, limited conclusions can be made about long-term DMF exposure during pregnancy or in utero. The results are also limited by the potential for underestimation of spontaneous abortions. Although TecGistry is an international registry, 70% of participants are from Germany, thus potentially limiting the transferability of these results to other countries.
Interim results from this large, international registry indicate that DMF exposure in the first trimester was not significantly associated with adverse pregnancy outcomes. The outcomes are consistent with previous reports of smaller groups of patients.4,5 Ongoing recruitment to this registry will allow the publication of outcomes up to 1 year of age and provide essential information on pregnancy outcomes among women exposed to DMF during pregnancy.
Study Funding
This study was sponsored by Biogen (Cambridge, MA). Funding for writing and editorial support was provided by Biogen.
Disclosure
K. Hellwig reports scientific advisory boards for Bayer, Biogen, Merck, Novartis, Roche, Sanofi, and Teva; speaker honoraria and research support from Bayer, Biogen, Genzyme, Merck, Novartis, Sanofi, and Teva; and support for congress participation from Bayer, Biogen, Genzyme, Merck, Roche, and Teva. D. Rog reports consulting fees from Biogen, Bristol Myers Squibb, Celgene, Hikma, MedDay, Merck Serono, Novartis, Roche, Sanofi, and Teva Neuroscience; research support from Actelion, Biogen, Merck Serono, Novartis, Sanofi, Teva Neuroscience, and TG Therapeutics; and speaker fees from Biogen, Merck Serono, Novartis, Roche, Sanofi, and Teva Neuroscience. C. McGuigan reports honoraria for consultancy work and/or research funding from Actelion, Biogen, Merck, Novartis, Roche, Sandoz, and Sanofi-Genzyme. M.K. Houtchens reports scientific advisory boards for Biogen, Merck, Novartis, Roche, Sanofi, and Teva and research support from Biogen, Genzyme, Merck, and Sanofi. D.R. Bruen reports scientific advisory boards for Biogen, Celgene, EMD Serono, Genentech, Novartis, and Sanofi-Genzyme. O. Mokliatchouk, F. Branco, X. Peng, and N.J. Everage are employees of and hold stock/stock options in Biogen. Go to Neurology.org/NN for full disclosures.
Acknowledgment
This study was sponsored by Biogen (Cambridge, MA). Cynthia C. Jones of Biogen (Cambridge, MA) was an integral part of the registry team and provided initial analysis and interpretation of the interim registry results. Gabrielle Knafler, PhD, and Karen Spach, PhD, of Excel Scientific Solutions (Fairfield, CT) provided initial editing support based on a draft from authors and incorporated author comments during revisions, and Nathaniel Hoover from Excel Scientific Solutions copyedited and styled the manuscript per journal requirements.
Appendix Authors
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
↵*Dr. Peng was an employee at Biogen at the time the research was conducted.
The Article Processing Charge was funded by Biogen.
- Received March 30, 2021.
- Accepted in final form October 14, 2021.
- Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
